University of Cambridge

Vaccine
#Covid-19 #Immunology / Virology & Vaccines #University of Cambridge

‘Universal’ vaccine could protect from several viruses at once 

A novel ‘universal’ vaccine has been engineered to provide protection from thousands of variants in one single dose.  Results from a first-in-human clinical trial, published in the Journal of Infection, show the vaccine protected participants from multiple Sarbeco coronaviruses, a large group of viruses including SARS-CoV-2, as… Read More

#News

#AI #Cancer research #Cervical cancer #Clinical trial #Colorectal cancer #Genetics / genomics #Head and neck cancer #MHRA #Obesity #Pistoia Alliance #Precision medicine #University College London #University of Cambridge #Weight loss

DDW Highlights: 9 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a cancer drug demonstrated it could reduce tumours by as much as… Read More

#Podcasts

#AI #Cancer research #Cervical cancer #Clinical trial #Colorectal cancer #Genetics / genomics #Head and neck cancer #MHRA #Obesity #Pistoia Alliance #Precision medicine #University College London #University of Cambridge #Weight loss

This week in Drug Discovery (1 June – 5 June) 

News round-up for 1 June – 5 June by Bruno Quinney, Content Team at DDW.  This week, a cancer drug has demonstrated it could reduce tumours by as much as 55%. Elsewhere, AI has been a recurrent theme in both clinical trials and drug development.   The top stories:… Read More

#News

Patient injects Ozempic
#Obesity #University College London #University of Cambridge #Weight loss

Obesity drugs could widen health inequalities, warn UK researchers

Without affordable, healthy food and appropriate support, obesity drugs such as semaglutide and tirzepatide could widen health inequalities, say researchers at UCL and the University of Cambridge.  In a correspondence published in Nature Medicine, the researchers argue that while incretin-based therapies… Read More

#News

#Neuroinflammation #Neuroscience #University of Cambridge

Collaboration set to develop neuroinflammation therapeutics 

Neuroscience company AndzonBio2 has announced it will collaborate with the University of Cambridge and Cambridge Enterprise to develop therapeutics for neuroinflammation.  The agreement states the parties will combine AndzonBio2’s expertise in early drug development and translational strategy with Cambridge’s world-leading neuroscience capabilities. This will also include the drug discovery platform developed… Read More

#News

Cancer cells
#Chemotherapy #Genetics / genomics #Oncology #University of Cambridge #Wellcome Sanger Institute

Chemotherapy finding could guide better treatments

For the first time, scientists have systematically studied the genetic effects of chemotherapy on healthy tissues.  Researchers from the Wellcome Sanger Institute, the University of Cambridge, Cambridge University Hospitals NHS Foundation Trust (CUH) and their collaborators analysed blood cell genomes from 23 patients of all ages who… Read More

#Cancer Research #News

Neurons
#Alzheimer's #Collaboration #Enhanced Genomics #Genetics / genomics #Multi-omics #Neuroscience #University of Cambridge

Genomics partnership discovers novel targets for Alzheimer’s

Biotechnology company Enhanced Genomics has announced a strategic partnership with The ALBORADA Drug Discovery Institute at the University of Cambridge.   Funded by Alzheimer’s Research UK, The ALBORADA Drug Discovery Institute is developing the next generation of treatments for the diseases that cause dementia.   The partnership… Read More

#News

Parkinson's disease
#Neurodegenerative disorders #Neuroscience #Parkinson's #University of Cambridge

Research reveals “compelling” new drug target for Parkinson’s

Researchers have identified a key enzyme driving forms of Parkinson’s, offering a promising new drug target for the condition.  In Parkinson’s, a protein known as alpha-synuclein builds up in clumps called Lewy bodies in nerve cells in the brain. These clumps of protein stop these cells from… Read More

#Editor's Choice #News

Tau proteins
#Alzheimer's #Neurodegenerative disorders #Tau protein #University of Cambridge

New therapy targets and destroys tau tangles in Alzheimer’s

Scientists have developed two new potential therapies that selectively remove aggregated tau proteins, which are associated with Alzheimer’s disease, and improve symptoms of neurodegeneration in mice. They say this promising approach could also be applied in future to other brain disorders driven by protein aggregation inside… Read More

#News #Trending News

Cancer cells
#Cancer drug targets #Genetics / genomics #Institute of Cancer Research #Oncology #University of Cambridge #Wellcome Sanger Institute

Researchers identify potential new genetic target for cancer drugs

UK researchers have mapped the exact variants in a gene that dramatically increase a person’s risk of developing cancer, paving the way for targeted treatment across diverse populations. Over 5,000 genetic variants that enable certain cancers to thrive were identified, along with a potential therapeutic target… Read More

#Cancer Research #News #Trending News

#Career #CRISPR #Drug discovery #Meet the Researcher #Milner Therapeutics Institute #University of Cambridge #Wet labs

Meet the researcher: Nicola McCarthy, Milner Therapeutics Institute

DDW’s Megan Thomas talks to Nicola McCarthy, Head of Research at the Milner Therapeutics Institute.  https://www.youtube.com/watch?v=MLnELbr7Nxc MT: Could you start by giving me your name, your job title and what you do?  NM: I'm Head of Research at the Milner Therapeutics Institute, which is part of the University of Cambridge, and I… Read More

#Exclusive Content #Opinion

#Coronavirus #Covid-19 #Covid-19 vaccine #Immunology / Virology & Vaccines #Pandemic prevention #University of Cambridge

‘Proactive’ vaccine protects against unknown future coronaviruses

Researchers have developed a new vaccine technology that can provide protection against a broad range of coronaviruses with potential for future disease outbreaks – including ones we don’t know about yet. This approach to vaccine development is called ‘proactive vaccinology’, where scientists build a vaccine before… Read More

#Editor's Choice #News

Blood cells
#Blood cancer #Gene mutation #Oncology #University of Cambridge #Wellcome Sanger Institute

Study reveals how genetic mutations combine to cause cancer

UK scientists have uncovered the interplay between cancer-driving genetic mutations and inherited genetic variants in a rare type of blood cancer. In the future, this knowledge could aid drug development and interventions that reduce the risk of disease. Researchers from the Wellcome Sanger Institute,… Read More

#Cancer Research #News

Pregnancy sickness
#Pregnancy #University of Cambridge #University of Southern California #Women's health

Scientists discover potential treatment for pregnancy sickness

A new study has shown why seven in 10 women experience nausea and vomiting during pregnancy – and why some women become so sick they need to be admitted to hospital. It is caused by GDF15, a hormone produced by the foetus. The new study suggests… Read More

#News

Embryonic stem cells
#Cell therapy #Multiple sclerosis #Stem cells #University of Cambridge #University of Colorado #University of Milano-Bicocca

Stem cell therapy shows promise in advanced MS

An international team of scientists has shown that a stem cell therapy for multiple sclerosis (MS) could prevent further damage to the brain. The early-stage clinical trial was the result of a collaboration between researchers at University of Colorado Anschutz Campus, the University of Cambridge and… Read More

#News #Trending News

Neurons
#Harvard Medical School #Mission Therapeutics #Neurodegenerative disorders #Neuroscience #Parkinson's #University of Cambridge

Potential disease-modifying therapy for Parkinson’s disease

An experimental drug has shown potential as a disease-modifying therapy for Parkinson’s disease, according to a new study published in Nature Communications. The peer-reviewed article titled ‘Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson’s disease (PD) mouse model’ was the result of collaborative… Read More

#Editor's Choice #News